Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Pontes, Caridad; Zara, Corinne; Torrent-Farnell, Josep; Obach, Merce; Nadal, Cristina; Vella-Bonanno, Patricia; Ermisch, Michael; Simoens, Steven; Hauegen, Renata Curi; Gulbinovic, Jolanta; Timoney, Angela; Martin, Antony P.; Mueller, Tanja; Nachtnebel, Anna; Campbell, Stephen; Selke, Gisbert; Bochenek, Tomasz; Rothe, Celia C.; Mardare, Ileana; Bennie, Marion; Fürst, Jurij; Malmstrom, Rickard E.; Godman, Brian.
Preprint en Inglés | PREPRINT-FIOCRUZ | ID: ppf-31008

Documentos relacionados

  1. [The first hospice for the dying in Europe? The 'Hundertsuppen'--hospital in Nuremberg 1770-1813].
  2. [What do we talk about when we talk about immigrant's health in Europe? Considerations from the 2nd Conference of Migrant Health in Europe].
  3. [Can western medicine resolve psychological problems in ethnic regions outside Europe? 2 cases from the region of Borneo-Sarawak].
  4. Biomedical research in france and brazil: an analysis of significant differences and ethical issues
  5. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
  6. New record of Cheyletiella parasitivorax (Mégnin, 1878) (Trombidiformes: Cheyletidae) from Brazil with an illustrated key to species for the genus
  7. [What is the future of internal medicine in Europe? Will it be apoptosis, necrosis or adaptation and remodeling?].
  8. How Can We Improve Education of Breast Surgeons Across Europe?
  9. China connecting Europe?
  10. Is there a "childless vote" in Europe?